IN2015DN04294A - - Google Patents

Info

Publication number
IN2015DN04294A
IN2015DN04294A IN4294DEN2015A IN2015DN04294A IN 2015DN04294 A IN2015DN04294 A IN 2015DN04294A IN 4294DEN2015 A IN4294DEN2015 A IN 4294DEN2015A IN 2015DN04294 A IN2015DN04294 A IN 2015DN04294A
Authority
IN
India
Prior art keywords
antibody moiety
polypeptides
protein conjugates
conjugate
conjugated
Prior art date
Application number
Inventor
Sasmita Tripathy
Michel Demeule
Jean Christophe Currie
Original Assignee
Angiochem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angiochem Inc filed Critical Angiochem Inc
Publication of IN2015DN04294A publication Critical patent/IN2015DN04294A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • C07K14/8117—Bovine/basic pancreatic trypsin inhibitor (BPTI, aprotinin)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

The present invention relates to protein conjugates comprising an aprotinin derived polypeptide which facilitates transport of the conjugate across the blood brain barrier and an antibody moiety that selectively binds a target within the CNS. The protein conjugates are further defined by the inclusion of a linker; by the number of polypeptides conjugated to each antibody moiety; by the positions at which the antibody moiety and the polypeptides are conjugated; and by the larger configuration of the conjugate (in which every polypeptide is linked only to the antibody moiety). Modified aprotinin derived polypeptides linker bound antibody moieties pharmaceutical compositions kits and methods of making and using the protein conjugates are also features of the invention.
IN4294DEN2015 2012-11-12 2013-11-12 IN2015DN04294A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261725365P 2012-11-12 2012-11-12
PCT/CA2013/050863 WO2014071531A1 (en) 2012-11-12 2013-11-12 Aprotinin-derived polypeptide-antibody conjugates

Publications (1)

Publication Number Publication Date
IN2015DN04294A true IN2015DN04294A (en) 2015-10-16

Family

ID=50683885

Family Applications (1)

Application Number Title Priority Date Filing Date
IN4294DEN2015 IN2015DN04294A (en) 2012-11-12 2013-11-12

Country Status (13)

Country Link
US (1) US20160213760A1 (en)
EP (1) EP2917244B1 (en)
JP (1) JP2015535523A (en)
CN (1) CN105026432A (en)
AU (1) AU2013344253A1 (en)
BR (1) BR112015010668A2 (en)
CA (1) CA2891190C (en)
DK (1) DK2917244T3 (en)
ES (1) ES2855169T3 (en)
IN (1) IN2015DN04294A (en)
MX (1) MX2015005982A (en)
RU (1) RU2015121818A (en)
WO (1) WO2014071531A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2471555A3 (en) 2005-07-15 2012-10-17 Angiochem Inc. Use of aprotinin polypeptides as carriers in pharmaceutical conjugates
EP2346906A4 (en) 2008-10-15 2013-04-24 Angiochem Inc Conjugates of glp-1 agonists and uses thereof
JP5759379B2 (en) 2008-12-05 2015-08-05 アンジオケム インコーポレーテッド Neurotensin or neurotensin analog and use thereof
JP2015526434A (en) 2012-08-14 2015-09-10 アンジオケム インコーポレーテッド Peptide-dendrimer conjugates and uses thereof
WO2016073833A1 (en) * 2014-11-06 2016-05-12 Cell Idx, Inc. High-affinity immunopolymers
JP7297408B2 (en) 2015-02-06 2023-06-26 セル アイディーエックス， インコーポレイテッド Immunoreagent coupled with antigen
EP3307326B9 (en) 2015-06-15 2021-02-24 Angiochem Inc. Methods for the treatment of leptomeningeal carcinomatosis
US20220073637A1 (en) * 2018-06-29 2022-03-10 City Of Hope Compositions and methods for treating autoimmune diseases
GB201906917D0 (en) * 2019-05-16 2019-07-03 Intract Pharma Ltd Novel compositions
WO2022099062A2 (en) * 2020-11-09 2022-05-12 The General Hospital Corporation Antibodies and single-chain variable region proteins recognizing click products

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090016959A1 (en) * 2005-02-18 2009-01-15 Richard Beliveau Delivery of antibodies to the central nervous system
EP2471555A3 (en) * 2005-07-15 2012-10-17 Angiochem Inc. Use of aprotinin polypeptides as carriers in pharmaceutical conjugates
CA2688344C (en) * 2007-05-29 2019-09-03 Angiochem, Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
AU2010239069B2 (en) * 2009-04-20 2015-05-14 Angiochem Inc Treatment of ovarian cancer using an anticancer agent conjugated to an Angiopep-2 analog
CN105999263B (en) * 2009-11-13 2021-06-29 第一三共欧洲有限公司 Materials and methods for treating or preventing human epidermal growth factor receptor-3 (HER-3) related diseases
US20130280281A1 (en) * 2010-07-02 2013-10-24 Jean-Paul Castaigne Short and d-amino acid-containing polypeptides for therapeutic conjugates and uses thereof
BR112012033295A2 (en) * 2010-07-02 2016-10-11 Angiochem Inc d-amino acid-containing short polypeptides for therapeutic conjugates and their use

Also Published As

Publication number Publication date
ES2855169T3 (en) 2021-09-23
ES2855169T8 (en) 2021-11-17
AU2013344253A1 (en) 2015-05-28
BR112015010668A2 (en) 2017-07-11
CN105026432A (en) 2015-11-04
CA2891190A1 (en) 2014-05-15
US20160213760A1 (en) 2016-07-28
EP2917244A1 (en) 2015-09-16
JP2015535523A (en) 2015-12-14
DK2917244T3 (en) 2021-03-08
CA2891190C (en) 2021-08-31
MX2015005982A (en) 2016-05-31
WO2014071531A1 (en) 2014-05-15
EP2917244B1 (en) 2021-01-06
RU2015121818A (en) 2017-01-10
EP2917244A4 (en) 2016-07-20

Similar Documents

Publication Publication Date Title
IN2015DN04294A (en)
UA110370C2 (en) Conjugates of amatoxin with improved linkages
EP2453908A4 (en) Bifunctional stapled polypeptides and uses thereof
AU2018256592A1 (en) Binding proteins comprising at least two repeat domains against HER2
CR20110358A (en) MYTHATIN LINK PROTEINS
MX2015005124A (en) Drug-protein conjugates.
IN2015DN02349A (en)
NZ703581A (en) Anti-cd70 antibody drug conjugates
CO2018009533A2 (en) Amanitin conjugates
IN2014CN03936A (en)
MX357193B (en) Anti-alpha synuclein binding molecules.
ECSP12012272A (en) PROTEINS THAT JOIN TNF-?
MX2012003939A (en) Drug fusions and conjugates with extended half life.
WO2012135854A3 (en) T cell receptor-like antibodies specific for a wt1 peptide presented by hla-a2
MX2012000765A (en) Improved anti-serum albumin binding single variable domains.
WO2013051878A3 (en) Antibody specifically binding to epitope in sema domain of c-met
MX2019006362A (en) Composition comprising two antibodies engineered to have reduced and increased effector function.
EA201391159A1 (en) HLA-Restricted Peptidospecific Antigen Binding Proteins
EA201001625A1 (en) HUMAN SERUM ALBUMIN LINKS AND THEIR CONJUGATES
WO2015095301A3 (en) Cytotoxic peptides and conjugates thereof
UA109888C2 (en) ANTIBODY OR ANTIBODILITY ANTIBODY OR ITS BINDING TO THE β-CLOTE, FGF RECEPTORS AND THEIR COMPLEXES
TN2014000120A1 (en) Cd27l antigen binding proteins
MD3665192T2 (en) Engineered transferrin receptor binding polypeptides
MX2013007067A (en) Anti-il-18 antibodies and their uses.
UA99339C2 (en) Antibody that specifically binds to human tyrp1